Published in Biol Psychiatry on February 07, 2014
The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol (2014) 0.99
The prefrontal cortex achieves inhibitory control by facilitating subcortical motor pathway connectivity. J Neurosci (2015) 0.94
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Dopaminergic modulation of motor network dynamics in Parkinson's disease. Brain (2015) 0.84
Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. J Psychopharmacol (2015) 0.84
The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos Trans R Soc Lond B Biol Sci (2015) 0.83
Cross-species studies of cognition relevant to drug discovery: A translational approach. Br J Pharmacol (2017) 0.80
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp (2016) 0.79
Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis (2015) 0.78
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. Neuropsychopharmacology (2016) 0.78
Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci (2017) 0.78
Atomoxetine restores the response inhibition network in Parkinson's disease. Brain (2016) 0.77
Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. Brain (2015) 0.76
Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. Mov Disord (2016) 0.75
Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease? Front Psychiatry (2016) 0.75
Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects. NPJ Parkinsons Dis (2017) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage (2006) 23.57
Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage (2008) 12.12
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34
An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci (2005) 9.32
On the ability to inhibit thought and action: general and special theories of an act of control. Psychol Rev (2014) 4.75
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain (2007) 3.62
Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage (2001) 3.51
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci (2007) 2.66
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Neurochemical modulation of response inhibition and probabilistic learning in humans. Science (2006) 2.41
Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition. J Neurosci (2009) 2.36
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) (2008) 2.07
Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry (2008) 1.89
Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia (1989) 1.87
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry (2007) 1.82
Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology (2007) 1.81
Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology (2006) 1.72
Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet (2005) 1.55
Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) (2004) 1.54
Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting. Neuroscience (2008) 1.51
Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurol Sci (2012) 1.47
Functional networks for cognitive control in a stop signal task: independent component analysis. Hum Brain Mapp (2011) 1.43
Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl) (2007) 1.42
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis (2010) 1.41
Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl) (2009) 1.36
The relationship between impulsive choice and impulsive action: a cross-species translational study. PLoS One (2012) 1.33
Lesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat. Eur J Neurosci (2007) 1.32
Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol (2010) 1.30
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. J Abnorm Child Psychol (2003) 1.25
Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl) (2008) 1.23
Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci (2011) 1.17
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord (2009) 1.16
Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry (2011) 1.15
Functional properties of the basal ganglia's re-entrant loop architecture: selection and reinforcement. Neuroscience (2011) 1.13
Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biol Psychiatry (2010) 1.12
Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. Proc Natl Acad Sci U S A (2010) 1.12
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology (2010) 1.11
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med (2012) 1.02
Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. Psychopharmacology (Berl) (2012) 1.02
Silent echo-planar imaging for auditory FMRI. MAGMA (2008) 1.01
Neurochemical enhancement of conscious error awareness. J Neurosci (2012) 1.01
Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res (2011) 1.00
Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. Biol Psychiatry (2010) 0.98
Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex (2012) 0.97
Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology (Berl) (2013) 0.97
Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: a multi-class pattern recognition approach. Neuroimage (2012) 0.96
Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol (2010) 0.95
Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? J Clin Exp Neuropsychol (2005) 0.94
The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci (2012) 0.93
Atomoxetine facilitates attentional set shifting in adolescent rats. Dev Cogn Neurosci (2011) 0.91
Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons. Neuropharmacology (2012) 0.89
Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology (2012) 0.88
Multiple modes of impulsivity in Parkinson's disease. PLoS One (2014) 0.87
Wavelet-based fMRI analysis: 3-D denoising, signal separation, and validation metrics. Neuroimage (2010) 0.83
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp (2016) 0.79
The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [(11)C]DASB positron emission tomography study. Neuropharmacology (2016) 0.75